Annual CFF
$18.98 M
+$18.74 M+7873.95%
31 December 2023
Summary:
Brainstorm Cell Therapeutics annual cash flow from financing activities is currently $18.98 million, with the most recent change of +$18.74 million (+7873.95%) on 31 December 2023. During the last 3 years, it has fallen by -$57.96 million (-75.33%). BCLI annual CFF is now -75.33% below its all-time high of $76.94 million, reached on 31 December 2020.BCLI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
-$4.37 M-100.00%
30 September 2024
Summary:
Brainstorm Cell Therapeutics quarterly cash flow from financing activities is currently $0.00, with the most recent change of -$4.37 million (-100.00%) on 30 September 2024. Over the past year, it has dropped by -$7.10 million (-100.00%). BCLI quarterly CFF is now -100.00% below its all-time high of $28.96 million, reached on 31 March 2020.BCLI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$10.26 M
-$7.10 M-40.89%
30 September 2024
Summary:
Brainstorm Cell Therapeutics TTM cash flow from financing activities is currently $10.26 million, with the most recent change of -$7.10 million (-40.89%) on 30 September 2024. Over the past year, it has dropped by -$5.60 million (-35.32%). BCLI TTM CFF is now -86.66% below its all-time high of $76.94 million, reached on 31 December 2020.BCLI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7873.9% | -100.0% | -35.3% |
| 3 y3 years | -75.3% | +100.0% | -63.3% |
| 5 y5 years | +57.3% | -100.0% | +224.6% |
BCLI Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -75.3% | +7873.9% | -100.0% | +100.0% | -63.3% | +7429.3% |
| 5 y | 5 years | -75.3% | +7873.9% | -100.0% | +100.0% | -86.7% | +7429.3% |
| alltime | all time | -75.3% | >+9999.0% | -100.0% | +100.0% | -86.7% | +7429.3% |
Brainstorm Cell Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $10.26 M(-40.9%) |
| June 2024 | - | $4.37 M(+72.1%) | $17.36 M(-5.1%) |
| Mar 2024 | - | $2.54 M(-24.3%) | $18.29 M(-3.6%) |
| Dec 2023 | $18.98 M(+7873.9%) | $3.35 M(-52.8%) | $18.98 M(+19.6%) |
| Sept 2023 | - | $7.10 M(+33.9%) | $15.86 M(+81.0%) |
| June 2023 | - | $5.30 M(+64.1%) | $8.77 M(+152.8%) |
| Mar 2023 | - | $3.23 M(+1257.1%) | $3.47 M(+1357.1%) |
| Dec 2022 | $238.00 K(-96.6%) | $238.00 K(>+9900.0%) | $238.00 K(-800.0%) |
| Sept 2022 | - | $0.00(0.0%) | -$34.00 K(-75.7%) |
| June 2022 | - | $0.00(0.0%) | -$140.00 K(0.0%) |
| Mar 2022 | - | $0.00(-100.0%) | -$140.00 K(-102.0%) |
| Dec 2021 | $6.97 M(-90.9%) | -$34.00 K(-67.9%) | $6.97 M(-75.1%) |
| Sept 2021 | - | -$106.00 K(<-9900.0%) | $27.94 M(-41.4%) |
| June 2021 | - | $0.00(-100.0%) | $47.67 M(-13.5%) |
| Mar 2021 | - | $7.11 M(-66.0%) | $55.09 M(-28.4%) |
| Dec 2020 | $76.94 M(+1372.5%) | $20.94 M(+6.7%) | $76.94 M(+32.5%) |
| Sept 2020 | - | $19.63 M(+164.7%) | $58.06 M(+39.6%) |
| June 2020 | - | $7.41 M(-74.4%) | $41.59 M(+21.7%) |
| Mar 2020 | - | $28.96 M(+1303.0%) | $34.18 M(+554.2%) |
| Dec 2019 | $5.22 M(-56.7%) | $2.06 M(-34.6%) | $5.22 M(+65.3%) |
| Sept 2019 | - | $3.16 M(>+9900.0%) | $3.16 M(+6098.0%) |
| June 2019 | - | $5000.00(>+9900.0%) | $51.00 K(-99.6%) |
| Mar 2019 | - | $0.00(0.0%) | $12.04 M(-0.2%) |
| Dec 2018 | $12.06 M(+3742.4%) | $0.00(-100.0%) | $12.06 M(-1.7%) |
| Sept 2018 | - | $46.00 K(-99.6%) | $12.27 M(-0.2%) |
| June 2018 | - | $11.99 M(>+9900.0%) | $12.30 M(+3529.2%) |
| Mar 2018 | - | $25.00 K(-88.0%) | $339.00 K(+8.0%) |
| Dec 2017 | $314.00 K(>+9900.0%) | $209.00 K(+178.7%) | $314.00 K(+199.0%) |
| Sept 2017 | - | $75.00 K(+150.0%) | $105.00 K(+250.0%) |
| June 2017 | - | $30.00 K(>+9900.0%) | $30.00 K(>+9900.0%) |
| Mar 2017 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2016 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2016 | - | $0.00(0.0%) | $111.00 K(0.0%) |
| June 2016 | - | $0.00(0.0%) | $111.00 K(-9.8%) |
| Mar 2016 | - | $0.00(-100.0%) | $123.00 K(-99.2%) |
| Dec 2015 | $14.87 M(+53.5%) | $111.00 K(>+9900.0%) | $14.87 M(+0.4%) |
| Sept 2015 | - | $0.00(-100.0%) | $14.80 M(-2.4%) |
| June 2015 | - | $12.00 K(-99.9%) | $15.17 M(-37.9%) |
| Mar 2015 | - | $14.74 M(>+9900.0%) | $24.43 M(+152.2%) |
| Dec 2014 | $9.69 M(+170.2%) | $46.00 K(-87.4%) | $9.69 M(+0.5%) |
| Sept 2014 | - | $366.00 K(-96.1%) | $9.64 M(-23.5%) |
| June 2014 | - | $9.27 M(>+9900.0%) | $12.60 M(+277.9%) |
| Mar 2014 | - | $0.00(-100.0%) | $3.33 M(-7.0%) |
| Dec 2013 | $3.58 M | $1000.00(-100.0%) | $3.58 M(+0.2%) |
| Sept 2013 | - | $3.33 M(>+9900.0%) | $3.58 M(-32.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | $7000.00(-97.2%) | $5.28 M(-2.2%) |
| Mar 2013 | - | $250.00 K(-5100.0%) | $5.40 M(+4.4%) |
| Dec 2012 | $5.17 M(+25.6%) | -$5000.00(-100.1%) | $5.17 M(+21.3%) |
| Sept 2012 | - | $5.03 M(+3890.5%) | $4.26 M(+665.4%) |
| June 2012 | - | $126.00 K(+530.0%) | $557.00 K(+17.3%) |
| Mar 2012 | - | $20.00 K(-102.2%) | $475.00 K(-88.5%) |
| Dec 2011 | $4.12 M(+90.6%) | -$911.00 K(-168.9%) | $4.12 M(-16.2%) |
| Sept 2011 | - | $1.32 M(+2904.5%) | $4.92 M(+22.3%) |
| June 2011 | - | $44.00 K(-98.8%) | $4.02 M(+0.3%) |
| Mar 2011 | - | $3.66 M(-3340.7%) | $4.01 M(+85.5%) |
| Dec 2010 | $2.16 M(+206.8%) | -$113.00 K(-126.5%) | $2.16 M(-15.2%) |
| Sept 2010 | - | $426.00 K(+1274.2%) | $2.55 M(+9.1%) |
| June 2010 | - | $31.00 K(-98.3%) | $2.34 M(-1.1%) |
| Mar 2010 | - | $1.82 M(+560.4%) | $2.36 M(+235.7%) |
| Dec 2009 | $704.00 K(-61.0%) | $275.00 K(+28.5%) | $704.00 K(+27.3%) |
| Sept 2009 | - | $214.00 K(+269.0%) | $553.00 K(-26.3%) |
| June 2009 | - | $58.00 K(-63.1%) | $750.00 K(-38.5%) |
| Mar 2009 | - | $157.00 K(+26.6%) | $1.22 M(-32.5%) |
| Dec 2008 | $1.81 M(-15.9%) | $124.00 K(-69.8%) | $1.81 M(-10.3%) |
| Sept 2008 | - | $411.00 K(-22.0%) | $2.01 M(-30.1%) |
| June 2008 | - | $527.00 K(-29.2%) | $2.88 M(+9.6%) |
| Mar 2008 | - | $744.00 K(+124.1%) | $2.63 M(+22.5%) |
| Dec 2007 | $2.15 M(+178.8%) | $332.00 K(-74.1%) | $2.15 M(+18.3%) |
| Sept 2007 | - | $1.28 M(+365.5%) | $1.81 M(+78.7%) |
| June 2007 | - | $275.00 K(+5.8%) | $1.02 M(-25.2%) |
| Mar 2007 | - | $260.00 K(-45.9%) | $1.36 M(-26.6%) |
| Dec 2006 | $770.00 K(-37.2%) | - | - |
| Sept 2006 | - | $480.60 K(-22.2%) | $1.85 M(+9.2%) |
| June 2006 | - | $617.40 K(0.0%) | $1.69 M(+38.2%) |
| Mar 2006 | - | $617.40 K(+357.3%) | $1.23 M(-7.2%) |
| Mar 2006 | $1.23 M(-16.3%) | - | - |
| Dec 2005 | - | $135.00 K(-58.3%) | $1.32 M(-30.2%) |
| Sept 2005 | - | $324.00 K(+116.7%) | $1.89 M(+21.3%) |
| June 2005 | - | $149.50 K(-79.0%) | $1.56 M(+6.6%) |
| Mar 2005 | $1.46 M(>+9900.0%) | $712.10 K(+0.8%) | $1.46 M(+92.9%) |
| Dec 2004 | - | $706.10 K(-9390.8%) | $759.00 K(+1257.8%) |
| Sept 2004 | - | -$7600.00(-114.2%) | $55.90 K(-12.0%) |
| June 2004 | - | $53.50 K(+664.3%) | $63.50 K(+535.0%) |
| Mar 2004 | $10.00 K(-152.4%) | $7000.00(+133.3%) | $10.00 K(-1528.6%) |
| Dec 2003 | - | $3000.00(>+9900.0%) | -$700.00(-93.7%) |
| Sept 2003 | - | $0.00(0.0%) | -$11.10 K(-41.9%) |
| June 2003 | - | $0.00(-100.0%) | -$19.10 K(0.0%) |
| Mar 2003 | -$19.10 K(+92.9%) | -$3700.00(-50.0%) | -$19.10 K(+24.0%) |
| Dec 2002 | - | -$7400.00(-7.5%) | -$15.40 K(+92.5%) |
| Sept 2002 | - | -$8000.00 | -$8000.00 |
| Mar 2002 | -$9900.00 | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual CFF year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly CFF year-on-year change?
- What is Brainstorm Cell Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM CFF year-on-year change?
What is Brainstorm Cell Therapeutics annual cash flow from financing activities?
The current annual CFF of BCLI is $18.98 M
What is the all time high annual CFF for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual cash flow from financing activities is $76.94 M
What is Brainstorm Cell Therapeutics annual CFF year-on-year change?
Over the past year, BCLI annual cash flow from financing activities has changed by +$18.74 M (+7873.95%)
What is Brainstorm Cell Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BCLI is $0.00
What is the all time high quarterly CFF for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly cash flow from financing activities is $28.96 M
What is Brainstorm Cell Therapeutics quarterly CFF year-on-year change?
Over the past year, BCLI quarterly cash flow from financing activities has changed by -$7.10 M (-100.00%)
What is Brainstorm Cell Therapeutics TTM cash flow from financing activities?
The current TTM CFF of BCLI is $10.26 M
What is the all time high TTM CFF for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM cash flow from financing activities is $76.94 M
What is Brainstorm Cell Therapeutics TTM CFF year-on-year change?
Over the past year, BCLI TTM cash flow from financing activities has changed by -$5.60 M (-35.32%)